The founder of the Solana ecosystem project Marginfi announced his resignation, due to disagreements with the team's way of doing things
PANews reported on April 11th that Edgar Pavlovsky, the founder of Solana's ecological margin protocol Marginfi, announced his departure from the Marginfi team on platform X. Edgar acknowledged that Marginfi is a world-class team, but he personally disagreed with their way of doing things internally or externally. He expressed his desire to devote his energy to work he believes is important for society.
Currently, lawyers are still resolving issues related to the founder's departure, but Edgar himself has already informed all relevant parties that he doesn't really care about tokens, money or anything else. Even though his recent financial situation has been very poor and personal income has almost dropped to zero. However, at present Edgar does not have any plans for next steps.
Earlier news revealed that Solend announced an airdrop for users who withdrew from MarginFi and deposited into Solend.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
